#ascendbybenchsci نتائج البحث
Today we launched a revolutionary platform to accelerate #DrugDiscovery. This was only made possible through strong partnerships with industry leaders like Philip Tagari & the @Amgen team. Learn about our collaboration & the creation of #ASCENDbyBenchSci: blog.benchsci.com/bringing-ascen…
Meet Omotola Komaiya, a Product Analyst by day and party planning enthusiast by night. She shares her role in the #ASCENDbyBenchSci launch, what #BlackHistoryMonth means to her, and what her favorite perk at work is. Read more of Omotola's story: blog.benchsci.com/working-at-the…
We're grateful to many of our customers, such as @Amgen, who were early adopters of #ASCENDbyBenchSci and who have already experienced significant improvements to their portfolio performance. Learn more about our latest technology: blog.benchsci.com/introducing-as… #ArtificialIntelligence
The increasing complexity of #DiseaseBiology makes new discoveries challenging, and scientists have been underserved for decades. #ASCENDbyBenchSci will help them make great leaps in productivity, taking their work and the industry forward. Learn more: blog.benchsci.com/introducing-as…
We’ve developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation, and uncover risks early to move the most promising projects forward faster. Read more about #ASCENDbyBenchSci: blog.benchsci.com/introducing-as…
Introducing #ASCENDbyBenchSci, an intuitive #AI #SaaS platform with the power to save pharma researchers years and millions in their preclinical research. blog.benchsci.com/introducing-as…
Congrats to our partner @BenchSci on the launch of #ASCENDbyBenchSci. We're honored to help introduce this revolutionary new #AI technology with the potential to transform preclinical research and bring medicine to patients faster. ow.ly/nwPv50MJ0iy
"Early adopters of #ASCENDbyBenchSci have reported improvements in the identification of new indications or targets (40%) & risks to safety or efficacy that improve R&D productivity (33%)." Read more about our latest technology via @Anjali_Sarkar @GENbio: genengnews.com/artificial-int…
genengnews.com
BenchSci Launches AI Tool to Map Disease Biology for Preclinical Drug Discovery
BenchSci has launched a new AI software that aims to expedite preclinical phase drug development pipelines by extracting biological insights underlying disease.
"A key challenge in #DrugDiscovery is better navigating the complexity of biology," said our CEO Liran Belenzon. That's where #ASCENDbyBenchSci comes in. Learn more about our #AI platform from @medicine_maker: themedicinemaker.com/discovery-deve…
It all started with a cup of coffee between Luigi Gentile, our CRO, and Philip Tagari, VP of Research at @Amgen. "What if we could harness our powerful AI technology to impact more areas of preclinical research?" asked Luigi. Read about #ASCENDbyBenchSci: blog.benchsci.com/bringing-ascen…
blog.benchsci.com
From Coffee to Collaboration: Bringing ASCEND to Life with AMGEN
How ASCEND came to be and the instrumental role Amgen played to help shape this revolutionary platform for preclinical pharmaceutical research
"We share our partners’ visions to help bring hope to patients faster. Our role in solving this enormous challenge is to develop and train technology that can change the world through the eyes and mind of scientists." #ASCENDbyBenchSci @OutsourcPharma outsourcing-pharma.com/Headlines/Clin…
"A key challenge in #DrugDiscovery is better navigating the complexity of biology," said our CEO Liran Belenzon. That's where #ASCENDbyBenchSci comes in. Learn more about our #AI platform from @medicine_maker: themedicinemaker.com/discovery-deve…
We're grateful to many of our customers, such as @Amgen, who were early adopters of #ASCENDbyBenchSci and who have already experienced significant improvements to their portfolio performance. Learn more about our latest technology: blog.benchsci.com/introducing-as… #ArtificialIntelligence
The increasing complexity of #DiseaseBiology makes new discoveries challenging, and scientists have been underserved for decades. #ASCENDbyBenchSci will help them make great leaps in productivity, taking their work and the industry forward. Learn more: blog.benchsci.com/introducing-as…
Meet Omotola Komaiya, a Product Analyst by day and party planning enthusiast by night. She shares her role in the #ASCENDbyBenchSci launch, what #BlackHistoryMonth means to her, and what her favorite perk at work is. Read more of Omotola's story: blog.benchsci.com/working-at-the…
It all started with a cup of coffee between Luigi Gentile, our CRO, and Philip Tagari, VP of Research at @Amgen. "What if we could harness our powerful AI technology to impact more areas of preclinical research?" asked Luigi. Read about #ASCENDbyBenchSci: blog.benchsci.com/bringing-ascen…
blog.benchsci.com
From Coffee to Collaboration: Bringing ASCEND to Life with AMGEN
How ASCEND came to be and the instrumental role Amgen played to help shape this revolutionary platform for preclinical pharmaceutical research
"We share our partners’ visions to help bring hope to patients faster. Our role in solving this enormous challenge is to develop and train technology that can change the world through the eyes and mind of scientists." #ASCENDbyBenchSci @OutsourcPharma outsourcing-pharma.com/Headlines/Clin…
We’ve developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation, and uncover risks early to move the most promising projects forward faster. Read more about #ASCENDbyBenchSci: blog.benchsci.com/introducing-as…
"Early adopters of #ASCENDbyBenchSci have reported improvements in the identification of new indications or targets (40%) & risks to safety or efficacy that improve R&D productivity (33%)." Read more about our latest technology via @Anjali_Sarkar @GENbio: genengnews.com/artificial-int…
genengnews.com
BenchSci Launches AI Tool to Map Disease Biology for Preclinical Drug Discovery
BenchSci has launched a new AI software that aims to expedite preclinical phase drug development pipelines by extracting biological insights underlying disease.
Congrats to our partner @BenchSci on the launch of #ASCENDbyBenchSci. We're honored to help introduce this revolutionary new #AI technology with the potential to transform preclinical research and bring medicine to patients faster. ow.ly/nwPv50MJ0iy
Today we launched a revolutionary platform to accelerate #DrugDiscovery. This was only made possible through strong partnerships with industry leaders like Philip Tagari & the @Amgen team. Learn about our collaboration & the creation of #ASCENDbyBenchSci: blog.benchsci.com/bringing-ascen…
Introducing #ASCENDbyBenchSci, an intuitive #AI #SaaS platform with the power to save pharma researchers years and millions in their preclinical research. blog.benchsci.com/introducing-as…
Today we launched a revolutionary platform to accelerate #DrugDiscovery. This was only made possible through strong partnerships with industry leaders like Philip Tagari & the @Amgen team. Learn about our collaboration & the creation of #ASCENDbyBenchSci: blog.benchsci.com/bringing-ascen…
We're grateful to many of our customers, such as @Amgen, who were early adopters of #ASCENDbyBenchSci and who have already experienced significant improvements to their portfolio performance. Learn more about our latest technology: blog.benchsci.com/introducing-as… #ArtificialIntelligence
The increasing complexity of #DiseaseBiology makes new discoveries challenging, and scientists have been underserved for decades. #ASCENDbyBenchSci will help them make great leaps in productivity, taking their work and the industry forward. Learn more: blog.benchsci.com/introducing-as…
We’ve developed new applications to empower scientists to discover biological connections, dramatically reduce trial-and-error experimentation, and uncover risks early to move the most promising projects forward faster. Read more about #ASCENDbyBenchSci: blog.benchsci.com/introducing-as…
Something went wrong.
Something went wrong.
United States Trends
- 1. Mateer 6,747 posts
- 2. Vandy 10.3K posts
- 3. Tim Banks 2,190 posts
- 4. #SurvivorSeries 24.9K posts
- 5. Michigan 148K posts
- 6. Heupel 1,601 posts
- 7. Pavia 4,806 posts
- 8. Oklahoma 25.6K posts
- 9. Tennessee 37K posts
- 10. Rutgers 3,640 posts
- 11. Ohio State 67.8K posts
- 12. Vanderbilt 7,518 posts
- 13. Arbuckle 1,231 posts
- 14. Venezuela 499K posts
- 15. Hawkins 13.1K posts
- 16. #Sooners 1,923 posts
- 17. Heisman 12.9K posts
- 18. Bono 8,701 posts
- 19. Neyland 1,675 posts
- 20. Malik Benson N/A